Physician profile
Anthony Bonfiglio
NPI 1144319104
$3,871.18
in general payments reported to CMS, 2019-2025
26 companies · $495 in 2025
The $495 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2020: $478 · 2021: $485 · 2022: $460 · 2023: $597 · 2024: $445 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,528 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.11 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $840.08 | 2019-2025 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $443.36 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $315.53 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $294.67 | 2019-2024 | Ilumya, Odomzo, Blu-U |
| Ucb, INC. | $211.92 | 2024-2025 | Bimzelx |
| Dermavant Sciences, INC. | $203.46 | 2023 | Vtama |
| Inari Medical, INC. | $194.23 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $170.17 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $169.98 | 2019-2022 | |
| Organon LLC | $168.40 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $154.34 | 2020-2021 | |
| Helsinn Therapeutics (U.S.), INC. | $120.55 | 2019 | |
| Amgen INC. | $117.41 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $105.68 | 2022-2024 | Sotyktu |
| Incyte Corporation | $60.25 | 2021-2023 | Opzelura |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $56.38 | 2019 | |
| Galderma Laboratories, L.P. | $56.30 | 2019-2025 | Nemluvio, Oracea, Aklief |
| Janssen Biotech, INC. | $44.31 | 2021-2024 | Simponi, Simponi Aria, Stelara |
| Leo Pharma INC. | $28.51 | 2022 | |
| Pfizer INC. | $27.50 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.40 | 2024 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.12 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $15.25 | 2021 | |
| Sebela Pharmaceuticals INC. | $15.00 | 2019 | |
| Genzyme Corporation | $14.14 | 2020 | |
| Prugen, INC. Pharmaceuticals | $9.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Bonfiglio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.